Terns Positive Clinical Data for TERN-701 in Relapsed/Refractory CML

Terns (NASDAQ: TERN) announced that Phase 1 CARDINAL data for TERN-701, an allosteric BCR::ABL1 inhibitor for previously treated CML, was selected for oral presentation at the 67th ASH Annual Meeting on December 8, 2025.

As of the June 30, 2025 cutoff (55 enrolled; 32 efficacy-evaluable), cumulative MMR was 75% (24/32) by 24 weeks, with 64% (14/22) achieving MMR and 100% (10/10) maintaining MMR. Safety was encouraging: no DLTs, MTD not reached, 87% remained on treatment, mostly low-grade TEAEs. Company will host an investor webcast on December 8, 2025 at 4:30pm ET.

https://www.stocktitan.net/news/TERN/terns-announces-abstract-with-positive-clinical-data-for-tern-701-in-ikkprtsxcdcw.html